Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease

Trial Profile

Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
    • 15 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Feb 2018.
    • 25 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top